Treatment of intermittent claudication: cilostazol (Review)

P. Collins, Julie Brittenden

Research output: Contribution to journalArticle

Abstract

Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.

Original languageEnglish
Pages (from-to)466-470
Number of pages4
JournalHospital Medicine
Volume65
Publication statusPublished - 2004

Keywords

  • PERIPHERAL ARTERIAL-DISEASE
  • QUALITY-OF-LIFE
  • CARDIOVASCULAR EVENTS
  • CONTROLLED TRIALS
  • VASCULAR-DISEASE
  • METAANALYSIS
  • WALKING
  • MULTICENTER
  • PREVENTION
  • MANAGEMENT

Cite this

Treatment of intermittent claudication: cilostazol (Review). / Collins, P.; Brittenden, Julie.

In: Hospital Medicine, Vol. 65, 2004, p. 466-470.

Research output: Contribution to journalArticle

@article{dac6c9ca465a4a81a6ab5905b2b0892f,
title = "Treatment of intermittent claudication: cilostazol (Review)",
abstract = "Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.",
keywords = "PERIPHERAL ARTERIAL-DISEASE, QUALITY-OF-LIFE, CARDIOVASCULAR EVENTS, CONTROLLED TRIALS, VASCULAR-DISEASE, METAANALYSIS, WALKING, MULTICENTER, PREVENTION, MANAGEMENT",
author = "P. Collins and Julie Brittenden",
year = "2004",
language = "English",
volume = "65",
pages = "466--470",
journal = "Hospital Medicine",
issn = "0441-2745",

}

TY - JOUR

T1 - Treatment of intermittent claudication: cilostazol (Review)

AU - Collins, P.

AU - Brittenden, Julie

PY - 2004

Y1 - 2004

N2 - Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.

AB - Intermittent claudication is a potentially disabling disorder that impairs quality of life and is a marker of underlying cardiovascular disease. Treatment involves secondary prevention and measures to improve walking. Cilostazol significantly increases walking distance and quality of life in claudicants.

KW - PERIPHERAL ARTERIAL-DISEASE

KW - QUALITY-OF-LIFE

KW - CARDIOVASCULAR EVENTS

KW - CONTROLLED TRIALS

KW - VASCULAR-DISEASE

KW - METAANALYSIS

KW - WALKING

KW - MULTICENTER

KW - PREVENTION

KW - MANAGEMENT

M3 - Article

VL - 65

SP - 466

EP - 470

JO - Hospital Medicine

JF - Hospital Medicine

SN - 0441-2745

ER -